BIOMAT Database Logo BIOMAT Database Logo

Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. 2002

S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
Hoosier Oncology Group, Walther Cancer Institute and Division of Hematology/Oncology, Indiana University, Indianapolis, IN, USA. shsoule@iupui.edu

BACKGROUND Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data suggest synergism with this combination. This phase II study evaluated the response rate and toxicity of docetaxel and estramustine in patients with metastatic breast cancer (MBC). METHODS Patients were treated with docetaxel 35 mg/m(2) on day 2 and estramustine phosphate 280 mg p.o. tds days 1-3 weekly for 3 of 4 weeks, for a maximum of six treatment cycles. RESULTS Thirty-nine patients were enrolled between August 1999 and March 2001; 36 were eligible. Of 31 evaluable patients, responses were observed in 15 patients (47%); two patients (6%) obtained a complete response. Median time to treatment failure was 6 months; median survival was 1 year. Thromboembolic toxicity occurred in 11% of patients: three experienced deep venous thromboses and one had a fatal pulmonary embolism. Myelosuppression was minimal with this regimen. CONCLUSIONS Despite modest activity in metastatic breast cancer, the toxicity observed with the combination of estramustine and docetaxel precludes the routine use of this combination in the treatment of breast cancer. Further studies using this compound in metastatic breast cancer are not warranted.

UI MeSH Term Description Entries
D008870 Microtubules Slender, cylindrical filaments found in the cytoskeleton of plant and animal cells. They are composed of the protein TUBULIN and are influenced by TUBULIN MODULATORS. Microtubule
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004961 Estramustine A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties. Estramustinphosphate,Emcyt,Estracyt,Estramustin Phosphate,Estramustine Phosphate Sodium,Leo-275,NSC-89199,Leo 275,Leo275,NSC 89199,NSC89199,Phosphate Sodium, Estramustine,Phosphate, Estramustin
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
Phase II study of weekly docetaxel in patients with metastatic breast cancer.
February 2002, Annals of oncology : official journal of the European Society for Medical Oncology,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study.
January 2005, Oncology,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer.
January 2005, Tumori,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
June 2006, Clinical breast cancer,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.
June 2007, Annals of oncology : official journal of the European Society for Medical Oncology,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
December 2006, Cancer chemotherapy and pharmacology,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
March 2003, Anti-cancer drugs,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
September 2004, Annals of oncology : official journal of the European Society for Medical Oncology,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
November 2005, Cancer chemotherapy and pharmacology,
S E Soule, and K D Miller, and P Porcu, and R Ansari, and F Fata, and J W McClean, and R Zon, and G W Sledge, and L H Einhorn
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
February 2003, Cancer,
Copied contents to your clipboard!